Dr Lindsay McGrath has been busy in 2020, acting as medical representative for the Queensland branch of an international Azura Ophthalmics clinical study, run through the Queensland University of Technology (QUT).
The trial is investigating a new drop for the management of meibomian gland dysfunction. Dr McGrath is the on-call ophthalmologist for the trial, approving baseline observations and blood tests, as well as being available to attend to any adverse events.
The trial is ongoing, and patients may be eligible to participate if they are 18 years or older, have had dry eye symptoms for at least 3 months and are willing to stop their current dry eye therapy for the trial. The trial lasts approximately 15 weeks and includes up to 6 visits at QUT Kelvin Grove campus.
For more information, patients or practitioners can contact Rohan Hughes email@example.com.